期刊文献+

尿苷二磷酸葡糖苷酸转移酶1A1基因多态性与胃癌临床病理特征及预后的相关性分析

Correlation of uridine diphosphate glucuronosyltransferase 1A1 polymorphism with clinicopathological features and prognosis of gastric cancer
原文传递
导出
摘要 目的探讨尿苷二磷酸葡糖苷酸转移酶1A1(UGT1A1)的基因多态性与胃癌患者临床病理特征及疾病预后的相关性,评估UGT1A1作为肿瘤标志物对于治疗胃癌及评估预后的价值。方法自2015年8月—2022年8月于本院就诊的206例胃癌患者收集胃癌组织标本。记录患者的基本信息、肿瘤情况、预后、肿瘤组织的UGT1A1基因型及病理学特征。分析基因型与胃癌临床病理特征、患者预后之间的相关性。结果在206例患者中,UGT1A1*6的野生型、杂合突变型、纯合突变型人数分别为166例(80.6%)、36例(17.5%)、4例(1.9%);UGT1A1*28的野生型、杂合突变型、纯合突变型人数分别为150例(72.8%)、48例(23.3%)、8例(3.9%)。UGT1A1*6在浸润性生长的胃癌、无家族史、无淋巴结转移的患者中更多见(P<0.05)。UGT1A1*28在≥55岁、无家族史及无饮酒史的管状腺胃癌患者中更常见(P<0.05),并与病理类型、肿瘤低分化、浸润性生长、T4具有相关性(P<0.05)。结论UGT1A1基因多态性与胃癌临床病理特征及预后显著相关。该基因可能作为肿瘤靶向治疗的潜在靶点,其临床应用潜力还有待进一步发掘。 Objective This paper aims to investigate the association of uridine diphosphate glucuronosyltransferase 1A1(UGT1A1)polymorphism with clinicopathological features and prognosis of gastric cancer patients,and to evaluate the potentiality of UGT1A1 as a biomarker for the treatment and prognosis prediction of gastric cancer.Methods From August 2015 to August 2022,gastric cancer specimens were collected from 206 patients with gastric cancer treated in our hospital.The basic information,tumor status,prognosis,UGT1A1 genotype and the pathological characteristics of tumor tissues were analyzed.The correlation of UGT1A1 gene expression with clinicopathological features and prognosis of gastric carcinoma was analyzed.Results Among the 206 patients,the number of wild type,heterozygous mutant and homozygous mutant of UGT1A1∗6 was 166(80.6%),36(17.5%)and 4(1.9%),respectively.There were 150(72.8%)cases of wild type,48(23.3%)cases of heterozygous mutant and 8(3.9%)cases of homozygous mutant in UGT1A1∗28.UGT1A1∗6 was more common in invasive gastric cancer,patients without family history and lymph node metastasis(P<0.05).UGT1A1∗28 was also more common in patients with tubular glandular stomach cancer,≥55 years old,no family history and no history of alcohol consumption(P<0.05);it was correlated with pathological type,low differentiation,invasive growth and T4(P<0.05).Conclusion UGT1A1 polymorphism was significantly associated with clinicopathologic features and prognosis of gastric cancer.This gene may be a potential target for tumor-targeted therapy,and its potential clinical application needs to be further explored.
作者 江德军 赵玉军 曾雪云 JIANG De-jun;ZHAO Yu-jun;ZENG Xue-yun(Quzhou Hospital Affiliated to Wenzhou Medical University(Quzhou People's Hospital),Zhejiang 324000,China)
出处 《中国卫生检验杂志》 CAS 2023年第15期1876-1879,共4页 Chinese Journal of Health Laboratory Technology
关键词 尿苷二磷酸葡糖苷酸转移酶1A1 基因多态性 胃癌 临床病理 预后 Uridine diphosphate glucuronosyltransferase 1A1 Polymorphism Gastric carcinoma Clinicopathology Prognosis
  • 相关文献

参考文献7

二级参考文献29

  • 1National Cancer Institute.Common Terminology Criteria for Adverse Events V3.0. http://ctep.cancer.gov/protocol Development/electronic_applications/docs/ctcaev3.pdf .
  • 2Rouits E,Charasson V,Pétain A,et al.Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer pa-tients[].British Journal of Cancer.2008
  • 3Chabot,GG.Clinical pharmacokinetics of irinotecan[].Clinical Pharmacokinetics.1997
  • 4F Innocenti,SD Undevia,L Iyer,PX Chen,S Das,M Kocherginsky,T Karrison,L Janisch,J Ramirez,CM Rudin,EE Vokes,MJ Ratain.Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan[].Clinical Oncology.2004
  • 5Ando Y,Saka H,Ando M,et al.Polymorphisms of UDPglucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis[].Cancer Research.2000
  • 6Massacesi C,Terrazzino S,Marcucci F,et al.Uridine diphos-phate glucuronosyl transferase 1A1 promoter polymorphism pre-dicts the risk of gastrointestinal toxicity and fatigue induced by iri-notecan-based chemotherapy[].Cancer.2006
  • 7Yong WP,Innocenti F,Ratain MJ.The role of pharmacogenetics in cancer therapeutics[].British Journal of Clinical Pharmacology.2006
  • 8Hall D,G Ybazeta,G Destro-Bisol,et al.Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates[].Pharmacogenetics.1999
  • 9Premawardhena,A,Fisher,CA,Liu,YT,Verma,IC,de,Silva,S,Arambepola,M.The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications[].Blood Cells Mol Diseases.2003
  • 10Zhang A,,Xing Q,Qin S,et al.Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase1A1gene in Chinese populations[].Pharmacogenomics.2007

共引文献105

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部